longer overall survival in metastatic tnbc with pembrolizumab - medpage today
Published 2 years ago • 123 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
11:53
new developments in triple-negative breast cancer therapies - medpage today
-
6:16
latest on immunotherapy in triple-negative breast cancer - medpage today
-
3:40
trodelvy improves qol in triple-negative breast cancer - medpage today
-
13:20
parp inhibitors for early, brca-mutant breast cancer - medpage today
-
3:21
atezo-chemo benefit in extensive-stage sclc seen outside trials, too - medpage today
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
3:53
stampede will 'change practice' in high-risk prostate cancer - medpage today
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
3:01
melanoma: is keytruda game-changing therapy?
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
3:13
atezolizumab in metastatic tnbc: long-term clinical outcomes and biomarker analyses
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
0:51
challenges in the treatment of mtnbc
-
0:15
3 year cancer survivor - stage 4 breast cancer at 22 #shorts
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
2:07
tnbc: using checkpoint inhibitors alone or with chemotherapy